Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immunocore Holdings plc IMCR
$60.21
+$1.38 (2.29%)
На 18:04, 12 мая 2023
+22.90%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2763920271.00000000
-
week52high
69.06
-
week52low
25.01
-
Revenue
143737000
-
P/E TTM
-54
-
Beta
0.55293300
-
EPS
-1.14000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 мар 2023 г. в 13:00
Описание компании
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Outperform | 08 авг 2022 г. | |
| BTIG | Buy | 02 авг 2022 г. | |
| HC Wainwright & Co. | Buy | 08 февр 2022 г. | |
| Oppenheimer | Outperform | 20 окт 2021 г. | |
| Jefferies | Buy | 02 мар 2021 г. | |
| JP Morgan | Overweight | Overweight | 14 сент 2022 г. |
| Morgan Stanley | Overweight | 09 сент 2022 г. | |
| Ladenburg Thalmann | Buy | 08 сент 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 13 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 21 ноя 2022 г. |
| Goldman Sachs | Buy | Neutral | 16 дек 2022 г. |
| Barclays | Overweight | 30 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Is Biotech Immunocore About To Make A 25% Price Move?
MarketBeat
07 февр 2023 г. в 07:00
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.
IPO Stock Of The Week: Biotech Leader Immunocore Approaches Latest Buy Point
Investors Business Daily
03 февр 2023 г. в 14:58
Biotech leader Immunocore is just below its latest buy point ahead of quarterly earnings results. The post IPO Stock Of The Week: Biotech Leader Immunocore Approaches Latest Buy Point appeared first on Investor's Business Daily.
Here is What to Know Beyond Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Trending Stock
Zacks Investment Research
01 февр 2023 г. в 10:32
Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.
Immunocore to present at upcoming investor conferences
GlobeNewsWire
01 февр 2023 г. в 07:00
Immunocore to present at upcoming investor conferences
3 Pharma Stocks That Will Mint Millionaires
InvestorPlace
30 янв 2023 г. в 10:20
In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB ) climbed 6% so far this year.